Targeting of desmoglein 1 in exfoliative toxin-mediated disease

References

• Ramos-e-Silva M, Pereira AL. Life-threatening eruptions due to infectious agents. Clin. Dermatol.23, 148–156 (2005).
   PubMed Web of Science ®Google Scholar
• Sladden MJ, Johnston GA. Common skin infections in children. BMJ329, 95–99 (2004).
   PubMed Web of Science ®Google Scholar
• Nishifuji K, Sugai M, Amagai M. Staphylococcal exfoliative toxins: ‘molecular scissors’ of bacteria that attack the cutaneous defense barrier in mammals. J. Dermatol. Sci.49, 21–31 (2008).
   PubMed Web of Science ®Google Scholar
• Cole C, Gazewood J. Diagnosis and treatment of impetigo. Am. Fam. Physician75, 859–864 (2007).
   PubMed Web of Science ®Google Scholar
• Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N. Engl. J. Med.355, 1800–1810 (2006).
   PubMed Web of Science ®Google Scholar
• Melish ME, Glasgow LA. The staphylococcal scalded-skin syndrome. N. Engl. J. Med.282, 1114–1119 (1970).
   PubMed Web of Science ®Google Scholar
• Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br. J. Dermatol.68, 355–361 (1956).
   PubMed Web of Science ®Google Scholar
• Cribier B, Piemont Y, Grosshans E. Staphylococcal scalded skin syndrome in adults. A clinical review illustrated with a new case. J. Am. Acad. Dermatol.30, 319–324 (1994).
   PubMed Web of Science ®Google Scholar
• Jefferson J. Lyell’s toxic epidermal necrolysis: a staphylococcal aetiology? Br. Med. J.2, 802–804 (1967).
   PubMed Web of Science ®Google Scholar
• Ladhani S. Understanding the mechanism of action of the exfoliative toxins of Staphylococcus aureus. FEMS Immunol. Med. Microbiol.39, 181–189 (2003).
   PubMedGoogle Scholar
• Oyake S, Oh-i T, Koga M. Staphylococcal scalded skin syndrome in a healthy adult. J. Dermatol.28, 145–148 (2001).
   PubMed Web of Science ®Google Scholar
• Suzuki R, Iwasaki S, Ito Y et al. Adult staphylococcus scalded skin syndrome in a peritoneal dialysis patient. Clin. Exp. Nephrol.7, 77–80 (2003).
   PubMedGoogle Scholar
• Shirin S, Gottlieb AB, Stahl EB. Staphylococcal scalded skin syndrome in an immunocompetent adult: possible implication of low-dosage prednisone. Cutis62, 223–224 (1998).
   PubMed Web of Science ®Google Scholar
• Farrell AM, Ross JS, Umasankar S, Bunker CB. Staphylococcal scalded skin syndrome in an HIV-1 seropositive man. Br. J. Dermatol.134, 962–965 (1996).
   PubMed Web of Science ®Google Scholar
• Opal SM, Johnson-Winegar AD, Cross AS. Staphylococcal scalded skin syndrome in two immunocompetent adults caused by exfoliatin B-producing Staphylococcus aureus. J. Clin. Microbiol.26, 1283–1286 (1988).
   PubMed Web of Science ®Google Scholar
• El Helali N, Carbonne A, Naas T et al. Nosocomial outbreak of staphylococcal scalded skin syndrome in neonates: epidemiological investigation and control. J. Hosp. Infect.61, 130–138 (2005).
   PubMed Web of Science ®Google Scholar
• Neylon O, O’Connell NH, Slevin B et al. Neonatal staphylococcal scalded skin syndrome: clinical and outbreak containment review. Eur. J. Pediatr.169(12), 1503–1509 (2010).
   PubMed Web of Science ®Google Scholar
• Dave J, Reith S, Nash JQ, Marples RR, Dulake C. A double outbreak of exfoliative toxin-producing strains of Staphylococcus aureus in a maternity unit. Epidemiol. Infect.112, 103–114 (1994).
   PubMed Web of Science ®Google Scholar
• Ladhani S. Recent developments in staphylococcal scalded skin syndrome. Clin. Microbiol. Infect.7, 301–307 (2001).
   PubMed Web of Science ®Google Scholar
• Ladhani S, Joannou CL, Lochrie DP, Evans RW, Poston SM. Clinical, microbial, and biochemical aspects of the exfoliative toxins causing staphylococcal scalded-skin syndrome. Clin. Microbiol. Rev.12, 224–242 (1999).
   PubMed Web of Science ®Google Scholar
• Patel GK. Treatment of staphylococcal scalded skin syndrome. Expert Rev. Anti Infect. Ther.2, 575–587 (2004).
   PubMedGoogle Scholar
• Foster TJ. Colonization and infection of the human host by staphylococci: adhesion, survival and immune evasion. Vet. Dermatol.20, 456–470 (2009).
   PubMed Web of Science ®Google Scholar
• Arbuthnott JP, Kent J, Lyell A, Gemmell CG. Toxic epidermal necrolysis produced by an extracellular product of Staphylococcus aureus. Br. J. Dermatol.85, 145–149 (1971).
   PubMed Web of Science ®Google Scholar
• Johnson AD, Metzger JF, Spero L. Production, purification, and chemical characterization of Staphylococcus aureus exfoliative toxin. Infect. Immun.12, 1206–1210 (1975).
   PubMed Web of Science ®Google Scholar
• Kapral FA, Miller MM. Skin lesions produced by Staphylococcus aureus exfoliatin in hairless mice. Infect. Immun.6, 877–879 (1972).
   PubMed Web of Science ®Google Scholar
• Kapral FA, Miller MM. Product of Staphylococcus aureus responsible for the scalded-skin syndrome. Infect. Immun.4, 541–545 (1971).
   PubMed Web of Science ®Google Scholar
• Patel GK, Finlay AY. Staphylococcal scalded skin syndrome: diagnosis and management. Am. J. Clin. Dermatol.4, 165–175 (2003).
   PubMed Web of Science ®Google Scholar
• de Dobbeleer G, Achten G. Staphylococcal scalded skin syndrome. An ultrastructural study. J. Cutan. Pathol.2, 91–98 (1975).
   PubMed Web of Science ®Google Scholar
• Melish ME, Glasgow LA, Turner MD, Lillibridge CB. The staphylococcal epidermolytic toxin: its isolation, characterization, and site of action. Ann. N Y Acad. Sci.236, 317–342 (1974).
   PubMed Web of Science ®Google Scholar
• Lillibridge CB, Melish ME, Glasgow LA. Site of action of exfoliative toxin in the staphylococcal scaled-skin syndrome. Pediatrics50, 728–738 (1972).
   PubMed Web of Science ®Google Scholar
• Olivry T, Linder KE. Dermatoses affecting desmosomes in animals: a mechanistic review of acantholytic blistering skin diseases. Vet. Dermatol.20, 313–326 (2009).
   PubMed Web of Science ®Google Scholar
• Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J. Clin. Invest.103, 461–468 (1999).
   PubMed Web of Science ®Google Scholar
• Amagai M. Autoimmunity against desmosomal cadherins in pemphigus. J. Dermatol. Sci.20, 92–102 (1999).
   PubMed Web of Science ®Google Scholar
• Coulombe PA, Kerns ML, Fuchs E. Epidermolysis bullosa simplex: a paradigm for disorders of tissue fragility. J. Clin. Invest.119, 1784–1793 (2009).
   PubMed Web of Science ®Google Scholar
• Olasz EB, Yancey KB. Bullous pemphigoid and related subepidermal autoimmune blistering diseases. Curr. Dir. Autoimmun.10, 141–166 (2008).
   PubMedGoogle Scholar
• Sladden MJ, Johnston GA. Current options for the treatment of impetigo in children. Expert Opin. Pharmacother.6, 2245–2256 (2005).
   PubMed Web of Science ®Google Scholar
• Johnston GA. Treatment of bullous impetigo and the staphylococcal scalded skin syndrome in infants. Expert Rev. Anti Infect. Ther.2, 439–446 (2004).
   PubMedGoogle Scholar
• Geria AN, Schwartz RA. Impetigo update: new challenges in the era of methicillin resistance. Cutis85, 65–70 (2010).
   PubMed Web of Science ®Google Scholar
• Ito Y, Funabashi Yoh M, Toda K, Shimazaki M, Nakamura T, Morita E. Staphylococcal scalded-skin syndrome in an adult due to methicillin-resistant Staphylococcus aureus. J. Infect. Chemother.8, 256–261 (2002).
   PubMedGoogle Scholar
• Acland KM, Darvay A, Griffin C, Aali SA, Russell-Jones R. Staphylococcal scalded skin syndrome in an adult associated with methicillin-resistant Staphylococcus aureus. Br. J. Dermatol.140, 518–520 (1999).
   PubMed Web of Science ®Google Scholar
• Noguchi N, Nakaminami H, Nishijima S, Kurokawa I, So H, Sasatsu M. Antimicrobial agent of susceptibilities and antiseptic resistance gene distribution among methicillin-resistant Staphylococcus aureus isolates from patients with impetigo and staphylococcal scalded skin syndrome. J. Clin. Microbiol.44, 2119–2125 (2006).
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Yokota Y, Terajima J et al. Clonal association of Staphylococcus aureus causing bullous impetigo and the emergence of new methicillin-resistant clonal groups in Kansai district in Japan. J. Infect. Dis.185, 1511–1516 (2002).
   PubMed Web of Science ®Google Scholar
• Nakaminami H, Noguchi N, Ikeda M et al. Molecular epidemiology and antimicrobial susceptibilities of 273 exfoliative toxin-encoding-gene-positive Staphylococcus aureus isolates from patients with impetigo in Japan. J. Med. Microbiol.57, 1251–1258 (2008).
   PubMed Web of Science ®Google Scholar
• Kondo I, Sakurai S, Sarai Y. New type of exfoliatin obtained from staphylococcal strains, belonging to phage groups other than group II, isolated from patients with impetigo and Ritter’s disease. Infect. Immun.10, 851–861 (1974).
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Nishifuji K, Sasaki M et al. Identification of the Staphylococcus aureus etd pathogenicity island which encodes a novel exfoliative toxin. ETD, and EDIN-B, Infect. Immun.70, 5835–5845 (2002).
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Hayashi T, Takami H et al. Complete nucleotide sequence of a Staphylococcus aureus exfoliative toxin B plasmid and identification of a novel ADP-ribosyltransferase. EDIN-C, Infect. Immun.69, 7760–7771 (2001).
   PubMed Web of Science ®Google Scholar
• O’Toole PW, Foster TJ. Molecular cloning and expression of the epidermolytic toxin A gene of Staphylococcus aureus. Microb. Pathog.1, 583–594 (1986).
   PubMed Web of Science ®Google Scholar
• Lee CY, Schmidt JJ, Johnson-Winegar AD, Spero L, Iandolo JJ. Sequence determination and comparison of the exfoliative toxin A and toxin B genes from Staphylococcus aureus. J. Bacteriol.169, 3904–3909 (1987).
   PubMed Web of Science ®Google Scholar
• Sato H, Matsumori Y, Tanabe T, Saito H, Shimizu A, Kawano J. A new type of staphylococcal exfoliative toxin from a Staphylococcus aureus strain isolated from a horse with phlegmon. Infect. Immun.62, 3780–3785 (1994).
   PubMed Web of Science ®Google Scholar
• Yamasaki O, Tristan A, Yamaguchi T et al. Distribution of the exfoliative toxin D gene in clinical Staphylococcus aureus isolates in France. Clin. Microbiol. Infect.12, 585–588 (2006).
   PubMed Web of Science ®Google Scholar
• Elsner P, Hartmann AA, Lenz W, Brandis H. Screening of clinical S. aureus-isolates for the production of exfoliative toxin. A methodological study. Zentralbl. Bakteriol. Mikrobiol. Hyg. A.260, 216–220 (1985).
   PubMedGoogle Scholar
• Yamasaki O, Yamaguchi T, Sugai M et al. Clinical manifestations of staphylococcal scalded-skin syndrome depend on serotypes of exfoliative toxins. J. Clin. Microbiol.43, 1890–1893 (2005).
   PubMed Web of Science ®Google Scholar
• Johnson AD, Spero L, Cades JS, de Cicco BT. Purification and characterization of different types of exfoliative toxin from Staphylococcus aureus. Infect. Immun.24, 679–684 (1979).
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Hayashi T, Takami H et al. Phage conversion of exfoliative toxin A production in Staphylococcus aureus. Mol. Microbiol.38, 694–705 (2000).
   PubMed Web of Science ®Google Scholar
• Dinges MM, Orwin PM, Schlievert PM. Exotoxins of Staphylococcus aureus. Clin. Microbiol. Rev.13, 16–34 (2000).
   PubMed Web of Science ®Google Scholar
• Schlievert PM. Role of superantigens in human disease. J. Infect. Dis.167, 997–1002 (1993).
   PubMed Web of Science ®Google Scholar
• Plano LR, Gutman DM, Woischnik M, Collins CM. Recombinant Staphylococcus aureus exfoliative toxins are not bacterial superantigens. Infect. Immun.68, 3048–3052 (2000).
   PubMed Web of Science ®Google Scholar
• Nishioka K, Nakano T, Hirao N, Asada Y. Staphylococcal scalded skin syndrome I. Purification of exfoliatin and maternal transmission of neutralizing ability against exfoliatin. J. Dermatol.4, 13–18 (1977).
   PubMedGoogle Scholar
• Machida K, Sakurai S, Kondo I, Ikawa S. Relationship between susceptibility and immune response to staphylococcal exfoliative toxin A in mammalian species. Microbiol. Immunol.32, 1079–1084 (1988).
   PubMed Web of Science ®Google Scholar
• Leung DY, Harbeck R, Bina P et al. Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J. Clin. Invest.92, 1374–1380 (1993).
   PubMed Web of Science ®Google Scholar
• Monday SR, Vath GM, Ferens WA et al. Unique superantigen activity of staphylococcal exfoliative toxins. J. Immunol.162, 4550–4559 (1999).
   PubMed Web of Science ®Google Scholar
• Morlock BA, Spero L, Johnson AD. Mitogenic activity of staphylococcal exfoliative toxin. Infect. Immun.30, 381–384 (1980).
   PubMed Web of Science ®Google Scholar
• Getsios S, Simpson CL, Kojima S et al. Desmoglein 1-dependent suppression of EGFR signaling promotes epidermal differentiation and morphogenesis. J. Cell. Biol.185, 1243–1258 (2009).
   PubMed Web of Science ®Google Scholar
• Gentilhomme E, Faure M, Piemont Y, Binder P, Thivolet J. Action of staphylococcal exfoliative toxins on epidermal cell cultures and organotypic skin. J. Dermatol.17, 526–532 (1990).
   PubMedGoogle Scholar
• Dancer SJ, Garratt R, Saldanha J, Jhoti H, Evans R. The epidermolytic toxins are serine proteases. FEBS Lett.268, 129–132 (1990).
   PubMed Web of Science ®Google Scholar
• Hanakawa Y, Schechter NM, Lin C, Nishifuji K, Amagai M, Stanley JR. Enzymatic and molecular characteristics of the efficiency and specificity of exfoliative toxin cleavage of desmoglein 1. J. Biol. Chem.279, 5268–5277 (2004).
   PubMed Web of Science ®Google Scholar
• Hanakawa Y, Selwood T, Woo D, Lin C, Schechter NM, Stanley JR. Calcium-dependent conformation of desmoglein 1 is required for its cleavage by exfoliative toxin. J. Invest. Dermatol.121, 383–389 (2003).
   PubMed Web of Science ®Google Scholar
• Papageorgiou AC, Plano LR, Collins CM, Acharya KR. Structural similarities and differences in Staphylococcus aureus exfoliative toxins A and B as revealed by their crystal structures. Protein Sci.9, 610–618 (2000).
   PubMed Web of Science ®Google Scholar
• Vath GM, Earhart CA, Monie DD, Iandolo JJ, Schlievert PM, Ohlendorf DH. The crystal structure of exfoliative toxin B: a superantigen with enzymatic activity. Biochemistry38, 10239–10246 (1999).
   PubMed Web of Science ®Google Scholar
• Vath GM, Earhart CA, Rago JV et al. The structure of the superantigen exfoliative toxin A suggests a novel regulation as a serine protease. Biochemistry36, 1559–1566 (1997).
   PubMed Web of Science ®Google Scholar
• Rago JV, Vath GM, Tripp TJ, Bohach GA, Ohlendorf DH, Schlievert PM. Staphylococcal exfoliative toxins cleave α- and β-melanocyte-stimulating hormones. Infect. Immun.68, 2366–2368 (2000).
   PubMed Web of Science ®Google Scholar
• Payne AS, Hanakawa Y, Amagai M, Stanley JR. Desmosomes and disease: pemphigus and bullous impetigo. Curr. Opin. Cell. Biol.16, 536–543 (2004).
   PubMed Web of Science ®Google Scholar
• Chernyavsky AI, Arredondo J, Kitajima Y, Sato-Nagai M, Grando SA. Desmoglein vs non-desmoglein signaling in pemphigus acantholysis: characterization of novel signaling pathways downstream of pemphigus vulgaris antigens. J. Biol. Chem.282(18), 13804–13812 (2007).
   PubMed Web of Science ®Google Scholar
• Nguyen VT, Ndoye A, Shultz LD, Pittelkow MR, Grando SA. Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions. J. Clin. Invest.106, 1467–1479 (2000).
   PubMed Web of Science ®Google Scholar
• Kurzen H, Brenner S. Significance of autoimmunity to non-desmoglein targets in pemphigus. Autoimmunity39, 549–556 (2006).
   PubMed Web of Science ®Google Scholar
• Ishii K, Lin C, Siegel DL, Stanley JR. Isolation of pathogenic monoclonal anti-desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies. J. Invest. Dermatol.128, 939–948 (2008).
   PubMed Web of Science ®Google Scholar
• Desai BV, Harmon RM, Green KJ. Desmosomes at a glance. J. Cell. Sci.122, 4401–4407 (2009).
   PubMed Web of Science ®Google Scholar
• Dusek RL, Godsel LM, Green KJ. Discriminating roles of desmosomal cadherins. Beyond desmosomal adhesion. J. Dermatol. Sci.45, 7–21 (2007).
   PubMed Web of Science ®Google Scholar
• Mahoney MG, Hu Y, Brennan D, Bazzi H, Christiano AM, Wahl JK 3rd. Delineation of diversified desmoglein distribution in stratified squamous epithelia: implications in diseases. Exp. Dermatol.15, 101–109 (2006).
   PubMed Web of Science ®Google Scholar
• Bazzi H, Getz A, Mahoney MG et al. Desmoglein 4 is expressed in highly differentiated keratinocytes and trichocytes in human epidermis and hair follicle. Differentiation74, 129–140 (2006).
   PubMed Web of Science ®Google Scholar
• Green KJ, Simpson CL. Desmosomes: new perspectives on a classic. J. Invest. Dermatol.127, 2499–2515 (2007).
   PubMed Web of Science ®Google Scholar
• Amagai M, Koch PJ, Nishikawa T, Stanley JR. Pemphigus vulgaris antigen (desmoglein 3) is localized in the lower epidermis, the site of blister formation in patients. J. Invest. Derm.106, 351–355 (1996).
   PubMed Web of Science ®Google Scholar
• Stanley JR, Koulu L, Klaus-Kovtun VK, Steinberg MS. A monoclonal antibody to the desmosomal glycoprotein desmoglein I binds the same polypeptide as human autoantibodies in pemphigus foliaceus. J. Immunol.136, 1227–1230 (1986).
   PubMed Web of Science ®Google Scholar
• Mahoney MG, Wang ZH, Rothenberger K, Koch PJ, Amagai M, Stanley JR. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus vulgaris. J. Clin. Invest.103, 461–468 (1999).
   PubMed Web of Science ®Google Scholar
• Hanakawa Y, Matsuyoshi N, Stanley JR. Expression of desmoglein 1 compensates for genetic loss of desmoglein 3 in keratinocyte adhesion. J. Invest. Dermatol.119, 27–31 (2002).
   PubMed Web of Science ®Google Scholar
• Brennan D, Hu Y, Medhat W, Dowling A, Mahoney MG. Superficial dsg2 expression limits epidermal blister formation mediated by pemphigus foliaceus antibodies and exfoliative toxins. Dermatol. Res. Pract.410278 (2010).
   PubMedGoogle Scholar
• Amagai M, Matsuyoshi N, Wang ZH, Andl C, Stanley JR. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nat. Med.6, 1275–1277 (2000).
   PubMed Web of Science ®Google Scholar
• Amagai M, Yamaguchi T, Hanakawa Y, Nishifuji K, Sugai M, Stanley JR. Staphylococcal exfoliative toxin B specifically cleaves desmoglein 1. J. Invest. Dermatol.118, 845–850 (2002).
   PubMed Web of Science ®Google Scholar
• Posthaus H, Dubois CM, Muller E. Novel insights into cadherin processing by subtilisin-like convertases. FEBS Lett.536, 203–208 (2003).
   PubMed Web of Science ®Google Scholar
• Yokouchi M, Saleh MA, Kuroda K et al. Pathogenic epitopes of autoantibodies in pemphigus reside in the amino-terminal adhesive region of desmogleins which are unmasked by proteolytic processing of prosequence. J. Invest. Dermatol.129(9), 2156–2166 (2009).
   PubMed Web of Science ®Google Scholar
• Amagai M, Ishii K, Takayanagi A, Nishikawa T, Shimizu N. Transport to endoplasmic reticulum by signal peptide, but not proteolytic processing, is required for formation of conformational epitopes of pemphigus vulgaris antigen (Dsg3). J. Invest. Dermatol.107, 539–542 (1996).
   PubMed Web of Science ®Google Scholar
• Shapiro L, Weis WI. Structure and biochemistry of cadherins and catenins. Cold Spring Harb. Perspect. Biol.1, a003053 (2009).
   PubMed Web of Science ®Google Scholar
• Amagai M, Ishii K, Hashimoto T, Gamou S, Shimizu N, Nishikawa T. Conformational epitopes of pemphigus antigens (Dsg1 and Dsg3) are calcium dependent and glycosylation independent. J. Invest. Derm.105, 243–247 (1995).
   PubMed Web of Science ®Google Scholar
• Amagai M, Hashimoto T, Green KJ, Shimizu N, Nishikawa T. Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus. J. Invest. Derm.105, 895–901 (1995).
   Google Scholar
• Payne AS, Ishii K, Kacir S et al. Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display. J. Clin. Invest.115, 888–899 (2005).
   PubMed Web of Science ®Google Scholar
• Chitaev NA, Troyanovsky SM. Direct Ca2+-dependent heterophilic interaction between desmosomal cadherins, desmoglein and desmocollin, contributes to cell-cell adhesion. J. Cell. Biol.138, 193–201 (1997).
   PubMed Web of Science ®Google Scholar
• Sekiguchi M, Futei Y, Fujii Y, Iwasaki T, Nishikawa T, Amagai M. Dominant autoimmune epitopes recognized by pemphigus antibodies map to the N-terminal adhesive region of desmogleins. J. Immunol.167, 5439–5448 (2001).
   PubMed Web of Science ®Google Scholar
• Getsios S, Amargo EV, Dusek RL et al. Coordinated expression of desmoglein 1 and desmocollin 1 regulates intercellular adhesion. Differentiation72, 419–433 (2004).
   PubMed Web of Science ®Google Scholar
• Waschke J, Bruggeman P, Baumgartner W, Zillikens D, Drenckhahn D. Pemphigus foliaceus IgG causes dissociation of desmoglein 1-containing junctions without blocking desmoglein 1 transinteraction. J. Clin. Invest.115, 3157–3165 (2005).
   PubMed Web of Science ®Google Scholar
• Spindler V, Heupel WM, Efthymiadis A et al. Desmocollin 3-mediated binding is crucial for keratinocyte cohesion and is impaired in pemphigus. J. Biol. Chem.284, 30556–30564 (2009).
   PubMed Web of Science ®Google Scholar
• Wheeler GN, Parker AE, Thomas CL et al. Desmosomal glycoprotein DGI, a component of intercellular desmosome junctions, is related to the cadherin family of cell adhesion molecules. Proc. Natl. Acad. Sci.88, 4796–4800 (1991).
   PubMed Web of Science ®Google Scholar
• Andl CD, Stanley JR. Central role of the plakoglobin-binding domain for desmoglein 3 incorporation into desmosomes. J. Invest. Dermatol.117, 1068–1074 (2001).
   PubMed Web of Science ®Google Scholar
• Chitaev NA, Leube RE, Troyanovsky RB, Eshkind LG, Franke WW, Troyanovsky SM. The binding of plakoglobin to desmosomal cadherins: patterns of binding sites and topogenic potential. J. Cell. Biol.133, 359–369 (1996).
   PubMed Web of Science ®Google Scholar
• Chitaev NA, Averbakh AZ, Troyanovsky RB, Troyanovsky SM. Molecular organization of the desmoglein-plakoglobin complex. J. Cell. Sci.111, 1941–1949 (1998).
   PubMed Web of Science ®Google Scholar
• Smith EA, Fuchs E. Defining the interactions between intermediate filaments and desmosomes. J. Cell. Biol.141, 1229–1241 (1998).
   PubMed Web of Science ®Google Scholar
• Chen X, Bonne S, Hatzfeld M, van Roy F, Green KJ. Protein binding and functional characterization of plakophilin 2. Evidence for its diverse roles in desmosomes and β-catenin signaling. J. Biol. Chem.277, 10512–10522 (2002).
   PubMed Web of Science ®Google Scholar
• Bonne S, Gilbert B, Hatzfeld M, Chen X, Green KJ, van Roy F. Defining desmosomal plakophilin-3 interactions. J. Cell. Biol.161, 403–416 (2003).
   PubMed Web of Science ®Google Scholar
• Kami K, Chidgey M, Dafforn T, Overduin M. The desmoglein-specific cytoplasmic region is intrinsically disordered in solution and interacts with multiple desmosomal protein partners. J. Mol. Biol.386, 531–543 (2009).
   PubMed Web of Science ®Google Scholar
• Mahoney MG, Simpson A, Aho S, Uitto J, Pulkkinen L. Interspecies conservation and differential expression of mouse desmoglein gene family. Exp. Dermatol.11, 115–125 (2002).
   PubMed Web of Science ®Google Scholar
• Brennan D, Hu Y, Kljuic A et al. Differential structural properties and expression patterns suggest functional significance for multiple mouse desmoglein 1 isoforms. Differentiation72, 434–449 (2004).
   PubMed Web of Science ®Google Scholar
• Troyanovsky SM, Troyanovsky RB, Eshkind LG, Krutovskikh VA, Leube RE, Franke WW. Identification of the plakoglobin-binding domain in desmoglein and its role in plaque assembly and intermediate filament anchorage. J. Cell. Biol.127, 151–160 (1994).
   PubMed Web of Science ®Google Scholar
• Norvell SM, Green KJ. Contributions of extracellular and intracellular domains of full length and chimeric cadherin molecules to junction assembly in epithelial cells. J. Cell. Sci.111, 1305–1318 (1998).
   PubMed Web of Science ®Google Scholar
• Serpente N, Marcozzi C, Roberts GA et al. Extracellularly truncated desmoglein 1 compromises desmosomes in MDCK cells. Mol. Membr. Biol.17, 175–183 (2000).
   PubMed Web of Science ®Google Scholar
• Troyanovsky SM, Eshkind LG, Troyanovsky RB, Leube RE, Franke WW. Contributions of cytoplasmic domains of desmosomal cadherins to desmosome assembly and intermediate filament anchorage. Cell72, 561–574 (1993).
   PubMed Web of Science ®Google Scholar
• Hanakawa Y, Schechter NM, Lin C et al. Molecular mechanisms of blister formation in bullous impetigo and staphylococcal scalded skin syndrome. J. Clin. Invest.110, 53–60 (2002).
   PubMed Web of Science ®Google Scholar
• Nishifuji K, Shimizu A, Ishiko A, Iwasaki T, Amagai M. Removal of amino-terminal extracellular domains of desmoglein 1 by staphylococcal exfoliative toxin is sufficient to initiate epidermal blister formation. J. Dermatol. Sci.59, 184–191 (2010).
   PubMed Web of Science ®Google Scholar
• Simpson CL, Kojima S, Cooper-Whitehair V, Getsios S, Green KJ. Plakoglobin rescues adhesive defects induced by ectodomain truncation of the desmosomal cadherin, desmoglein 1. Implications for exfoliative toxin-mediated skin blistering. Am. J. Pathol. (2010) (In press).
   Google Scholar
• Heupel WM, Zillikens D, Drenckhahn D, Waschke J. Pemphigus vulgaris IgG directly inhibit desmoglein 3-mediated transinteraction. J. Immunol.181, 1825–1834 (2008).
   PubMed Web of Science ®Google Scholar
• Calkins CC, Setzer SV, Jennings JM et al. Desmoglein endocytosis and desmosome disassembly are coordinated responses to pemphigus autoantibodies. J. Biol. Chem.281, 7623–7634 (2006).
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Aoyama Y, Shu E, Tsunoda K, Amagai M, Kitajima Y. Anti-desmoglein 3 (Dsg3) monoclonal antibodies deplete desmosomes of Dsg3 and differ in their Dsg3-depleting activities related to pathogenicity. J. Biol. Chem.282, 17866–17876 (2007).
   PubMed Web of Science ®Google Scholar
• Kitajima Y. Mechanisms of desmosome assembly and disassembly. Clin. Exp. Dermatol.27, 684–690 (2002).
   PubMed Web of Science ®Google Scholar
• Aoyama Y, Kitajima Y. Pemphigus vulgaris-IgG causes a rapid depletion of desmoglein 3 (Dsg3) from the Triton X-100 soluble pools, leading to the formation of Dsg3-depleted desmosomes in a human squamous carcinoma cell line. DJM-1 cells. J. Invest. Dermatol.112, 67–71 (1999).
   PubMed Web of Science ®Google Scholar
• Williamson L, Raess NA, Caldelari R et al. Pemphigus vulgaris identifies plakoglobin as key suppressor of c-Myc in the skin. EMBO J.25, 3298–3309 (2006).
   PubMed Web of Science ®Google Scholar
• Lee HE, Berkowitz P, Jolly PS, Diaz LA, Chua MP, Rubenstein DS. Biphasic activation of p38MAPK suggests that apoptosis is a downstream event in pemphigus acantholysis. J. Biol. Chem.284, 12524–12532 (2009).
   PubMed Web of Science ®Google Scholar
• Rubenstein DS, Diaz LA. Pemphigus antibody induced phosphorylation of keratinocyte proteins. Autoimmunity39, 577–586 (2006).
   PubMed Web of Science ®Google Scholar
• Waschke J, Spindler V, Bruggeman P, Zillikens D, Schmidt G, Drenckhahn D. Inhibition of Rho A activity causes pemphigus skin blistering. J. Cell. Biol.175, 721–727 (2006).
   PubMed Web of Science ®Google Scholar
• Kawasaki Y, Aoyama Y, Tsunoda K, Amagai M, Kitajima Y. Pathogenic monoclonal antibody against desmoglein 3 augments desmoglein 3 and p38 MAPK phosphorylation in human squamous carcinoma cell line. Autoimmunity39, 587–590 (2006).
   PubMed Web of Science ®Google Scholar
• Berkowitz P, Diaz LA, Hall RP, Rubenstein DS. Induction of p38MAPK and HSP27 phosphorylation in pemphigus patient skin. J. Invest. Dermatol.128, 738–740 (2008).
   PubMed Web of Science ®Google Scholar
• Berkowitz P, Hu P, Liu Z et al. Desmosome signaling. Inhibition of p38MAPK prevents pemphigus vulgaris IgG induced cytoskeleton reorganization. J. Biol. Chem.280, 23778–23784 (2005).
   PubMed Web of Science ®Google Scholar
• Berkowitz P, Hu P, Warren S, Liu Z, Diaz LA, Rubenstein DS. p38MAPK inhibition prevents disease in pemphigus vulgaris mice. Proc. Natl Acad. Sci. USA103, 12855–12860 (2006).
   PubMed Web of Science ®Google Scholar
• Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs69, 1911–1934 (2009).
   PubMed Web of Science ®Google Scholar
• Miller MM, Kapral FA. Neutralization of Staphylococcus aureus exfoliatin by antibody. Infect. Immun.6, 561–563 (1972).
   PubMed Web of Science ®Google Scholar
• Simpson CL, Kojima S, Getsios S. RNA interference in keratinocytes and an organotypic model of human epidermis. Methods Mol. Biol.585, 127–146 (2010).
   PubMedGoogle Scholar
• Descargues P, Deraison C, Bonnart C et al. Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat. Genet.37, 56–65 (2005).
   PubMed Web of Science ®Google Scholar
• Descargues P, Deraison C, Prost C et al. Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrome. J. Invest. Dermatol.126, 1622–1632 (2006).
   PubMed Web of Science ®Google Scholar
• Hachem JP, Wagberg F, Schmuth M et al. Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. J. Invest. Dermatol.126, 1609–1621 (2006).
   PubMed Web of Science ®Google Scholar
• Chao SC, Richard G, Lee JY. Netherton syndrome: report of two Taiwanese siblings with staphylococcal scalded skin syndrome and mutation of SPINK5. Br. J. Dermatol.152, 159–165 (2005).
   PubMed Web of Science ®Google Scholar
• Anzai H, Stanley JR, Amagai M. Production of low titers of anti-desmoglein 1 IgG autoantibodies in some patients with staphylococcal scalded skin syndrome. J. Invest. Dermatol.126, 2139–2141 (2006).
   PubMed Web of Science ®Google Scholar
• Kanzaki H, Ueda M, Morishita Y, Akiyama H, Arata J, Kanzaki S. Producibility of exfoliative toxin and staphylococcal coagulase types of Staphylococcus aureus strains isolated from skin infections and atopic dermatitis. Dermatology195, 6–9 (1997).
   PubMed Web of Science ®Google Scholar
• Yagi S, Wakaki N, Ikeda N. Presence of staphylococcal exfoliative toxin A in sera of patients with atopic dermatitis. Clin. Exp. Allergy34, 984–993 (2004).
   PubMed Web of Science ®Google Scholar